diagnostics

Harbinger Health foreshadows launch of blood-based cancer screening platform with $140M VC round
Harbinger Health foreshadows launch of blood-based cancer screening platform with $140M VC round
Fierce Biotech
Harbinger Health
Medtech
diagnostics
cancer
funding
liquid biopsy
Flag link:
Free COVID tests by mail are back, starting Monday
Free COVID tests by mail are back, starting Monday
NPR
COVID-19
Joe Biden
diagnostics
Flag link:
GE HealthCare Receives Boost in its Bid to Design AI-Assisted Tools
GE HealthCare Receives Boost in its Bid to Design AI-Assisted Tools
Medical Devices and Diagnostics Industry
GE Healthcare
artificial intelligence
Gates Foundation
Medtech
diagnostics
ultrasound
Flag link:
Illumina leads $15m investment in Broken String Biosciences
Illumina leads $15m investment in Broken String Biosciences
Clinical Trials Arena
Broken String Biosciences
Illumina
diagnostics
Medtech
funding
geonomics
Flag link:
Walgreens to pay $44M to settle claims over fraudulent Theranos tests
Walgreens to pay $44M to settle claims over fraudulent Theranos tests
Medtech Dive
legal
Medtech
diagnostics
Walgreens Boots Alliance
Theranos
fraud
Flag link:
Guardant abandons cancer blood test trial early, restates confidence in product line
Guardant abandons cancer blood test trial early, restates confidence in product line
Medtech Dive
Medtech
diagnostics
Guardant Health
colon cancer
Flag link:
Illumina names successor to former CEO de Souza
Illumina names successor to former CEO de Souza
Pharmaphorum
Illumina
diagnostics
Medtech
Jacob Thaysen
Francis deSouza
Flag link:
23andMe Granted New FDA Clearance to Report Additional BRCA Variants
23andMe Granted New FDA Clearance to Report Additional BRCA Variants
Drugs.com
23andMe
BRCA
diagnostics
FDA
Flag link:
Illumina’s Contrasting Announcements Send Mixed Messages
Illumina’s Contrasting Announcements Send Mixed Messages
Medical Devices and Diagnostics Industry
Illumina
diagnostics
layoffs
California
India
Flag link:
SEC Investigating Illumina’s Multi-Billion Dollar Merger with GRAIL
SEC Investigating Illumina’s Multi-Billion Dollar Merger with GRAIL
BioSpace
SEC
Illumina
Grail
M&A
cancer
diagnostics
Flag link:
More Alzheimer's Treatments Are Coming: This Company Can Help With Early Detection
More Alzheimer's Treatments Are Coming: This Company Can Help With Early Detection
Motley Fool
Alzheimer's disease
diagnostics
Quest Diagnostics
Flag link:
Illumina Slides After Slashing Full-Year Forecast
Illumina Slides After Slashing Full-Year Forecast
Yahoo/Bloomberg
Illumina
diagnostics
earnings
Flag link:
Why 23andMe Holding Stock Plummeted by 13% Today
Why 23andMe Holding Stock Plummeted by 13% Today
Motley Fool
earnings
23andMe
diagnostics
genetics
Flag link:
Guardant, Illumina Settle Patent Suit, Renew Long-Term Commercial Partnership
Guardant, Illumina Settle Patent Suit, Renew Long-Term Commercial Partnership
360Dx
Guardant Health
Illumina
diagnostics
Medtech
legal
Flag link:
Researchers Develop Cutting-Edge Assay for Diabetes
Researchers Develop Cutting-Edge Assay for Diabetes
Medical Devices and Diagnostics Industry
diabetes
diagnostics
Indian Institute of Science
somatostatin
Flag link:
Grail sued by three female ex-employees over ‘toxic work culture’
Grail sued by three female ex-employees over ‘toxic work culture’
FT.com
Grail
diagnostics
legal
sexual harrassment
racial discrimination
Flag link:
A New Day Is Coming for the Diagnostics Industry
A New Day Is Coming for the Diagnostics Industry
Medical Devices and Diagnostics Industry
M&A
Medtech
diagnostics
EDP Biotech
New Day Diagnostics
Flag link:
Illumina starts job cuts, plans office exit to rein in costs
Illumina starts job cuts, plans office exit to rein in costs
Yahoo/Reuters
Illumina
layoffs
diagnostics
Flag link:
Artificial intelligence advances cancer diagnostics in the next decade
Artificial intelligence advances cancer diagnostics in the next decade
Clinical Trials Arena
diagnostics
Medtech
artificial intelligence
cancer
oncology
Mindpeak
Proscia
Flag link:
Exact Sciences’ next-gen colorectal cancer test hits primary goals in pivotal study
Exact Sciences’ next-gen colorectal cancer test hits primary goals in pivotal study
Medtech Dive
EXACT Sciences
Medtech
diagnostics
colorectal cancer
Cologuard
clinical trials
Flag link:

Pages